Vistagen enters exclusive negotiation with Fuji Pharma for PH80 in Japan; receives $1.5M upfront

Vistagen Therapeutics, Inc.

Fuji Pharma pays $1.5M non-refundable for up to ~18-month exclusive negotiation for PH80 license in Japan.
PH80 is a neuroactive nasal spray for acute treatment of moderate to severe menopausal hot flashes.
Exploratory Phase 2A showed statistically significant reduction in hot flash frequency and severity vs placebo.
If a definitive license agreement is signed, the $1.5M will be creditable against the signing fee.
Neither party is obligated to reach a definitive agreement; negotiations may terminate after exclusive period.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Vistagen Therapeutics, Inc. entered into Exclusive Negotiation Agreement with Fuji Pharma Co., Ltd. valued at $1,500,000 (effective 2023-09-01).

Action: entry
Agreement: license
Counterparty: Fuji Pharma Co., Ltd.
Value: $1,500,000
Effective: 2023-09-01

Exact text from the filing

On September 1, 2023, Vistagen Therapeutics, Inc. (the “ Company ”) entered into an Exclusive Negotiation Agreement (the “ Negotiation Agreement ”) by and among the Company and Fuji Pharma Co., Ltd.

View on SEC.gov

300 material agreements filed in the last 30 days. Browse all material agreements →

Vistagen Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-23-025509

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.